Newsroom

CymaBay Therapeutics to Present at Three Investor Conferences

5 days ago

NEWARK, Calif., Nov. 13, 2017 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will provide a corporate overview at the 29th Annual Piper Jaffray Healthcare Conference, the Evercore/ISI 2017 Biopharma Catalyst/Deep Dive Conference, and the Global Mizuho Investor Conference.

29th Annual Piper Jaffray Healthcare Conference
Date: Wednesday, November 29
Time: 12:00pm Eastern time
Location: Lotte New York Palace Hotel
Webcast: http://ir.cymabay.com/events

Evercore/ISI 2017 Biopharma Catalyst/Deep Dive Conference
Date: Thursday, November 30
Time: 12:05pm Eastern Time
Location: Boston Harbor Hotel
Webcast: http://ir.cymabay.com/events

Global Mizuho Investor Conference
Date: Tuesday, December 5
Time: One-on-One Format
Location: Lotte New York Palace Hotel

About CymaBay 
CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. Seladelpar is a potent and selective agonist of PPARδ, a nuclear receptor that regulates genes involved in bile acid/sterol, lipid and glucose metabolism and inflammation. Seladelpar is currently in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Two Phase 2 studies of seladelpar established proof of concept in PBC. CymaBay is currently planning to advance development of seladelpar into Phase 3 for PBC and Phase 2 for NASH. Arhalofenate is a potential urate-lowering anti-flare therapy that has been found to reduce painful flares in joints while at the same time lowering serum uric acid by promoting excretion of uric acid by the kidney. This dual action addresses both the signs and symptoms of gout while managing the underlying pathophysiology of hyperuricemia. Arhalofenate has been licensed in the U.S. to Kowa Pharmaceuticals America, Inc.  CymaBay retains full development and commercialization rights for arhalofenate outside the U.S.

For additional information about CymaBay visit www.cymabay.com.

Contact:               
Hans Vitzthum
LifeSci Advisors, LLC
212-915-2568
Hans@LifeSciAdvisors.com

Stock Information

Investor Toolkit

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address